QRG Capital Management Inc. Raises Position in Cencora, Inc. $COR

QRG Capital Management Inc. lifted its position in shares of Cencora, Inc. (NYSE:COR) by 22.5% during the fourth quarter, HoldingsChannel reports. The fund owned 14,255 shares of the company’s stock after acquiring an additional 2,623 shares during the quarter. QRG Capital Management Inc.’s holdings in Cencora were worth $4,815,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after buying an additional 5,543 shares in the last quarter. AustralianSuper Pty Ltd acquired a new position in Cencora during the third quarter worth $26,191,000. Mediolanum International Funds Ltd raised its position in Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after acquiring an additional 32,138 shares in the last quarter. Chilton Investment Co. Inc. acquired a new stake in Cencora in the third quarter valued at $459,000. Finally, Advisors Asset Management Inc. boosted its position in shares of Cencora by 40.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after purchasing an additional 4,973 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on COR. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. Evercore set a $360.00 target price on shares of Cencora in a report on Wednesday, April 8th. Morgan Stanley set a $380.00 price target on Cencora in a research note on Tuesday, March 17th. Barclays upped their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $398.17.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Company raised full‑year adjusted EPS guidance and authorized buyback — management bumped FY2026 adjusted EPS to $17.65–$17.90 and approved a $1 billion repurchase program, which supports shareholder returns and offsets some concerns about near‑term sales. Cencora raises annual profit forecast despite quarterly miss
• Positive Sentiment: Margin expansion and specialty wins — adjusted gross margins expanded ~45 bps, driven in part by the OneOncology integration and strong international operating income, signaling progress toward higher‑margin services. Cencora lifts 2026 outlook after OneOncology-fueled earnings jump
• Positive Sentiment: Quarterly dividend declared — board approved a $0.60 per‑share quarterly dividend (ex‑dividend May 15), modest yield but adds to cash return profile for income‑oriented shareholders.
• Neutral Sentiment: Top‑line growth but below expectations — revenue rose ~3.8% YoY to ~$78.4B, demonstrating underlying growth yet missing consensus and leaving investors focused on mix and client dynamics. Cencora Reports Fiscal 2026 Second Quarter Results
• Negative Sentiment: Earnings and revenue miss drove the selloff — adjusted EPS $4.75 missed expectations (~$4.80) and revenue missed estimates, prompting heavy investor selling and a sharp share decline. Cencora (COR) Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: Revenue guidance trimmed vs. Street — management’s revenue range came in below consensus, citing slower U.S. Healthcare Solutions sales, branded‑drug price cuts and lower volumes to a large mail‑order client. That downgrade to top‑line expectations is weighing on the stock. Cencora Shares Drop on Revenue Outlook Cut
• Negative Sentiment: Operational headwinds and market worries — reports note negative operating cash flow, customer losses, and margin pressure from GLP‑1 related mix; visible insider selling has also added to investor caution. Cencora Stock (COR) Opinions on Q2 Earnings Release
• Negative Sentiment: Technicals and sentiment: stock hit a fresh 52‑week low amid the reaction, increasing short‑term downside risk until clarity on U.S. segment recovery and cash‑flow stabilization. Cencora hits 52-week low after guidance cut

Cencora Trading Down 17.2%

Shares of COR stock opened at $253.20 on Thursday. The company has a market capitalization of $49.25 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 1.43 and a beta of 0.64. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The firm has a 50-day moving average price of $330.01 and a 200 day moving average price of $342.75.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the prior year, the firm earned $4.42 EPS. The business’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts forecast that Cencora, Inc. will post 17.58 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.